<div id="readability-page-1">09:14 AM EST, 01/06/2026 (MT Newswires) -- Health care stocks were rising premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF ( XLV ) and iShares Biotechnology ETF (IBB) up 0.3%.Alumis ( ALMS ) stock surged by more than 133% after the company said its investigational oral drug envudeucitinib achieved &#34;superior&#34; skin clearance compared with placebo in two phase 3 trials in patients with moderate to severe plaque psoriasis.GSK (GSK) shares were up more than 3% after the company said Japan's Ministry of Health, Labour and Welfare has approved Exdensur as a treatment for severe bronchial asthma and chronic rhinosinusitis with nasal polyps.Alkermes ( ALKS ) stock was up more than 3% after the company said the US Food and Drug Administration granted breakthrough therapy designation to alixorexton for the treatment of narcolepsy type 1, a neurological disorder. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

葛蘭素史克

阿爾凱默斯

醫療保健股票在週二盤前上漲，State Street Health Care Select Sector SPDR ETF (XLV) 和 iShares Biotechnology ETF (IBB) 上漲了 0.3%。Alumis (ALMS) 在其藥物 envudeucitinib 在銀屑病試驗中顯示出優越結果後，股價飆升超過 133%。GSK (GSK) 的股價在日本批准 Exdensur 用於重度哮喘後上漲超過 3%。Alkermes (ALKS) 在獲得 FDA 對 alixorexton 用於 1 型嗜睡症的突破性療法認證後，股價也上漲超過 3%

板塊更新：醫療保健類股在週二盤前上漲